Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial

Nylander, Malin; Frøssing, Signe; Clausen, Helle V.; Kistorp, Caroline; Faber, Jens; Skouby, Sven O.

doi:10.1016/j.rbmo.2017.03.023

Cited by 73 publications

(85 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GLP-1 agonists also have an established role in obesity due to their effects on appetite and food intake from their actions in the gut to delay gastric emptying and in the brain [ 176 ]. In small studies, the GLP-1 receptor agonist liraglutide has been shown to have beneficial effects in both NAFLD and PCOS [ 177 , 178 ]. The beneficial effects may be secondary to weight loss rather than direct effects on insulin sensitivity and cellular metabolic pathways.…”

Section: Approaches To Prevent or Reverse The Progression From Mhomentioning

confidence: 99%

Exploring Therapeutic Targets to Reverse or Prevent the Transition from Metabolically Healthy to Unhealthy Obesity

Dagpo

Nolan

Delghingaro-Augusto

2020

Cells

View full text Add to dashboard Cite

The prevalence of obesity and obesity-related metabolic comorbidities are rapidly increasing worldwide, placing a huge economic burden on health systems. Excessive nutrient supply combined with reduced physical exercise results in positive energy balance that promotes adipose tissue expansion. However, the metabolic response and pattern of fat accumulation is variable, depending on the individual’s genetic and acquired susceptibility factors. Some develop metabolically healthy obesity (MHO) and are resistant to obesity-associated metabolic diseases for some time, whereas others readily develop metabolically unhealthy obesity (MUO). An unhealthy response to excess fat accumulation could be due to susceptibility intrinsic factors (e.g., increased likelihood of dedifferentiation and/or inflammation), or by pathogenic drivers extrinsic to the adipose tissue (e.g., hyperinsulinemia), or a combination of both. This review outlines the major transcriptional factors and genes associated with adipogenesis and regulation of adipose tissue homeostasis and describes which of these are disrupted in MUO compared to MHO individuals. It also examines the potential role of pathogenic insulin hypersecretion as an extrinsic factor capable of driving the changes in adipose tissue which cause transition from MHO to MUO. On this basis, therapeutic approaches currently available and emerging to prevent and reverse the transition from MHO to MUO transition are reviewed.

show abstract

Section: Approaches To Prevent or Reverse The Progression From Mhomentioning

confidence: 99%

Exploring Therapeutic Targets to Reverse or Prevent the Transition from Metabolically Healthy to Unhealthy Obesity

Dagpo

Nolan

Delghingaro-Augusto

2020

Cells

View full text Add to dashboard Cite

show abstract

“…Der Effekt von Antidiabetika wie Liraglutid und Empagliflozin ist Gegenstand von Studien. Diese weisen vereinzelt positive Daten zur Reduktion von Gewicht, Hyperandrogenämie, Anovulation und zur Schwangerschaftsrate unter IVF auf [16][17][18][19][20]. Der Einsatz ist derzeit als experimentell zu betrachten und für die Patientinnen auch im Rahmen der Indikation der Lifestyle-Medikation oder eines Off-Label-Use kostenintensiv.…”

Section: Ausblickunclassified

Das polyzystische Ovarsyndrom: Aktuelle Evidenz und praktische Empfehlungen

Tan¹,

Böing²,

Führer-Sakel³

2020

Diabetologie und Stoffwechsel

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in women of childbearing age. Due to hyperandrogenism and chronic anovulation affected women may suffer from hirsutism, androgenetic alopecia, acne, menstrual disturbance and sub-/infertility. Furthermore underlying insulin resistance promotes hyperandrogenemia, overweight and risk for diabetes. Therefore, routine evaluation of glycemic status is recommended. Treatment strategies are based on therapeutic lifestyle changes and focus on patient-important complaints. First line pharmacologic treatment for infertility in women with PCOS is letrozole. Clomiphene and metformin can be used alternatively with lower success rates. Women seeking medical advice for hyperandrogenism can be offered oral contraceptive pills with the lowest effective estrogen dose without any preference of a certain gestagen. Risk for deep vein thrombosis should be taken into account when choosing estrogen dose and type of gestagen. Antiandrogen substances such as spironolactone should only be prescribed in combination with safe contraception due to their risk of fetal undervirilisation. Additionally, substance specific risks should be considered. Baseline treatment of overweight or metabolic issues includes behaviour modification, weight reduction and physical activity. Additional benefit can be reached by combination of lifestyle changes with metformin. Studies indicate a positive effect of inositol and antidiabetic substances like liraglutide and empagliflozin but should be regarded as experimental therapies.

show abstract

“…The most recent study reported that liraglutide improved bleeding ratio and decreased ovarian volume with liraglutide when compared to placebo [61]. Moreover, after liraglutide discontinuation, one small 12-week study conducted with 40 infertile PCOS reported an increase of fertility potential.…”

Section: Rasmussen Andmentioning

confidence: 99%

Incretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome

Sever¹,

Ferjan²

2018

Debatable Topics in PCOS Patients

View full text Add to dashboard Cite

Introduction: Obesity is highly prevalent in polycystic ovary syndrome (PCOS). It aggravates adverse features of the syndrome. Weight management by lifestyle intervention is often insufficient. We reviewed studies addressing the use of agents mediating through incretin system in obese PCOS. Material and methods: Available relevant clinical trials were searched from PubMed. Results: Intervention with glucagon-like peptide 1 (GLP-1) analogue liraglutide is associated with consistent body mass index (BMI) reduction in treatment-naive obese women with PCOS and in poor responders to metformin and lifestyle modification. We recognized metformin as a well-suited combination with liraglutide. We demonstrated that liraglutide could also improve eating behavior and fertility potential in obese PCOS. Furthermore, we challenged the potential association of variability of GLP-1 receptor genotype and interindividual differences in response to liraglutide. In addition, we introduced the original concept related to the enhancement of incretin axis through phosphodiesterase 4 (PDE4). Nevertheless, we considered dipeptidyl peptidase 4 inhibitors as an alternative pharmacological intervention in metformin intolerant patients with PCOS. Conclusion: Agents mediating through incretin system in combination with lifestyle intervention and metformin could improve treatment outcomes in obese PCOS patients. Further studies are needed to establish the benefit/risk profile achieved by these potential new treatment strategies.

show abstract

Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial

Cited by 73 publications

References 28 publications

Exploring Therapeutic Targets to Reverse or Prevent the Transition from Metabolically Healthy to Unhealthy Obesity

Exploring Therapeutic Targets to Reverse or Prevent the Transition from Metabolically Healthy to Unhealthy Obesity

Das polyzystische Ovarsyndrom: Aktuelle Evidenz und praktische Empfehlungen

Incretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome

Contact Info

Product

Resources

About